These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032 [TBL] [Abstract][Full Text] [Related]
3. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates. Gouvea IE; Izidoro MA; Judice WA; Cezari MH; Caliendo G; Santagada V; dos Santos CN; Queiroz MH; Juliano MA; Young PR; Fairlie DP; Juliano L Arch Biochem Biophys; 2007 Jan; 457(2):187-96. PubMed ID: 17184724 [TBL] [Abstract][Full Text] [Related]
4. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells. Hamill P; Jean F Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392 [TBL] [Abstract][Full Text] [Related]
5. A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations. Mao SS; DiMuzio J; McHale C; Burlein C; Olsen D; Carroll SS Anal Biochem; 2008 Feb; 373(1):1-8. PubMed ID: 18022380 [TBL] [Abstract][Full Text] [Related]
6. Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction. Liu Y; Kati W; Chen CM; Tripathi R; Molla A; Kohlbrenner W Anal Biochem; 1999 Feb; 267(2):331-5. PubMed ID: 10036138 [TBL] [Abstract][Full Text] [Related]
7. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
8. Investigating the origin of the slow-binding inhibition of HCV NS3 serine protease by a novel substrate based inhibitor. Liu Y; Saldivar A; Bess J; Solomon L; Chen CM; Tripathi R; Barrett L; Richardson PL; Molla A; Kohlbrenner W; Kati W Biochemistry; 2003 Jul; 42(29):8862-9. PubMed ID: 12873147 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of a fluorogenic interleukin-1 beta converting enzyme substrate based on resonance energy transfer. Pennington MW; Thornberry NA Pept Res; 1994; 7(2):72-6. PubMed ID: 8012123 [TBL] [Abstract][Full Text] [Related]
12. A high-throughput radiometric assay for hepatitis C virus NS3 protease. Cerretani M; Di Renzo L; Serafini S; Vitelli A; Gennari N; Bianchi E; Pessi A; Urbani A; Colloca S; De Francesco R; Steinkühler C; Altamura S Anal Biochem; 1999 Jan; 266(2):192-7. PubMed ID: 9888975 [TBL] [Abstract][Full Text] [Related]
13. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Taliani M; Bianchi E; Narjes F; Fossatelli M; Urbani A; Steinkühler C; De Francesco R; Pessi A Anal Biochem; 1996 Aug; 240(1):60-7. PubMed ID: 8811880 [TBL] [Abstract][Full Text] [Related]
14. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics. Goudreau N; Brochu C; Cameron DR; Duceppe JS; Faucher AM; Ferland JM; Grand-Maître C; Poirier M; Simoneau B; Tsantrizos YS J Org Chem; 2004 Sep; 69(19):6185-201. PubMed ID: 15357576 [TBL] [Abstract][Full Text] [Related]
15. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
16. Assessment of substrate specificity of hepatitis G virus NS3 protease by a genetic method. Lee YJ; Kang H; Rho SH; Eom SH; Park WJ Biochem Biophys Res Commun; 2001 Aug; 286(1):171-5. PubMed ID: 11485324 [TBL] [Abstract][Full Text] [Related]
17. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies. Bonneau PR; Plouffe C; Pelletier A; Wernic D; Poupart MA Anal Biochem; 1998 Jan; 255(1):59-65. PubMed ID: 9448842 [TBL] [Abstract][Full Text] [Related]
18. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
19. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Zhang R; Beyer BM; Durkin J; Ingram R; Njoroge FG; Windsor WT; Malcolm BA Anal Biochem; 1999 Jun; 270(2):268-75. PubMed ID: 10334844 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the West Nile virus protease substrate specificity and inhibitors. Mueller NH; Yon C; Ganesh VK; Padmanabhan R Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]